Malignant transformation of hyperplastic gastric polyps: An immunohistochemical and pathological study of the changes of neoplastic phenotype

Imura,Johji; Hayashi,Shinichi; Ichikawa,Kazuhito; Miwa,Shigeharu; Nakajima,Takahiko; Nomoto,Kazuhiro; Tsuneyama,Koichi; Nogami,Tatsuya; Saitoh,Hitoaki; Fujimori,Takahiro

doi:10.3892/ol.2014.1932

Malignant transformation of hyperplastic gastric polyps: An immunohistochemical and pathological study of the changes of neoplastic phenotype

Authors:
- Johji Imura
- Shinichi Hayashi
- Kazuhito Ichikawa
- Shigeharu Miwa
- Takahiko Nakajima
- Kazuhiro Nomoto
- Koichi Tsuneyama
- Tatsuya Nogami
- Hitoaki Saitoh
- Takahiro Fujimori
View Affiliations

Affiliations: Department of Diagnostic Pathology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930‑0194, Japan, Department of Molecular and Surgical Pathology, Dokkyo Medical University School of Medicine, Mibu, Tochigi 321‑0293, Japan, Department of Pathology, Ibaraki Prefectural Central Hospital, Kasama, Ibaraki 309‑1793, Japan
Published online on: March 4, 2014 https://doi.org/10.3892/ol.2014.1932
Pages: 1459-1463

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In spite of the evidence that the malignant transformation of gastric hyperplastic polyps (HPs) is a rare event, it must always be taken into account during diagnosis. The aim of the current study was to clarify the mechanism of the malignant transformation of gastric hyperplasia polyps, with focus on phenotypic expression, cell proliferation and p53 overexpression. Immunohistochemistry for mucin phenotypic markers, including MUC1, MUC2, MUC5AC, MUC6, tight junction factors (claudin‑3, ‑4 and ‑18), an intestinal phenotypic marker [caudal type homeobox 2 (Cdx2)], Ki‑67 proliferative index and p53 overexpression, was performed on archival specimens of gastric polyps excised from six patients. Histologically, the intermingled components of several lesions were present in these polyps. Furthermore, the cancer components were predominantly differentiated adenocarcinoma. Immunohistochemically, all hyperplastic components expressed MUC5AC, but did not exhibit positivity for MUC2. Additionally, the majority of hyperplastic components were immunonegative for claudin‑3, while claudin‑3 positivity was observed in the majority of areas of dysplasia and carcinoma. Expression of claudin‑4 was also observed in the majority of cases and claudin‑18 was preserved in the hyperplastic, dysplastic and adenocarcinomatous lesions of all cases. Nuclear accumulation of Cdx2 was detected in almost all the samples with dysplasia and carcinoma, while nuclear p53 was detected in 24‑80% of the dysplastic areas and >85% of the cancer components. The Ki‑67 labeling index appeared to correlate with neoplastic progression. The observations provided evidence that the mechanism underlying malignant transformation of gastric HPs may occur by multistep carcinogenesis, such as the hyperplasia‑adenoma (dysplasia)‑adenocarcinoma sequence, and these neoplastic cells may acquire various phenotypes during this process.

View Figures

View References

1	Ueno K, Oshiba S, Yamagata S, et al: Histo-clinical classification and follow-up study of gastric polyp. Tohoku J Exp Med. 118(Suppl): S23–S38. 1976. View Article : Google Scholar
2	Kozuka S, Masamoto K, Suzuki S, et al: Histogenetic types and size of polypoid lesions in the stomach, with special reference to cancerous change. Gann. 68:267–274. 1977.
3	Laxén F, Sipponen P, Ihamäki T, et al: Gastric polyps; their morphological and endoscopical characteristics and relation to gastric carcinoma. Acta Pathol Microbiol Immunol Scand A. 90:221–228. 1982.PubMed/NCBI
4	Hattori T: Morphological range of hyperplastic polyps and carcinomas arising in hyperplastic polyps of the stomach. J Clin Pathol. 38:622–630. 1985. View Article : Google Scholar : PubMed/NCBI
5	Daibo M, Itabashi M and Hirota T: Malignant transformation of gastric hyperplastic polyps. Am J Gastroenterol. 82:1016–1025. 1987.
6	Zea-Iriarte WL, Sekine I, Itsuno M, et al: Carcinoma in gastric hyperplastic polyps. A phenotypic study. Dig Dis Sci. 41:377–386. 1996. View Article : Google Scholar : PubMed/NCBI
7	Orlowska J and Kupryjanczyk J: Malignant transformation of gastric hyperplastic polyps. Am J Clin Pathol. 117:165–166. 2002.PubMed/NCBI
8	Ajiki T, Nakamura T, Suehiro I, et al: Increased immunohistochemical labeling indices as indicators of malignant transformation of a gastric hyperplastic polyp. Am J Gastroenterol. 97:211–212. 2002. View Article : Google Scholar
9	Bosseckert H, Kratzsch KH, Machnik G, et al: Hyperplasiogenic polyps and stomach carcinoma risk-experiences following 1074 polypectomies and follow-up studies. Schweiz Rundsch Med Prax. 79:537–539. 1990.(In German).
10	Gschwantler M, Pulgram T, Feichtenschlager T, et al: Gastric carcinoma arising from a hyperplasiogenic polyp with a diameter of less than 2 centimeters. Z Gastroenterol. 33:610–612. 1995.
11	Joffe N and Antonioli DA: Atypical appearances of benign hyperplastic gastric polyps. AJR. 131:147–152. 1978. View Article : Google Scholar : PubMed/NCBI
12	Orlowska J, Jarosz D, Pachlewski J and Butruk E: Malignant transformation of benign epithelial gastric polyps. Am J Gastroenterol. 90:2152–2159. 1995.PubMed/NCBI
13	Remmele W and Kolb EF: Malignant transformation of hyperplasiogenic polyps of the stomach - case report. Endoscopy. 10:63–65. 1978. View Article : Google Scholar : PubMed/NCBI
14	Yao T, Kajiwara M, Kuroiwa S, et al: Malignant transformation of gastric hyperplastic polyps: alteration of phenotypes, proliferative activity, and p53 expression. Hum Pathol. 33:1016–1022. 2002. View Article : Google Scholar : PubMed/NCBI
15	Tatematsu M, Ichinose M, Miki K, et al: Gastric and intestinal phenotypic expression of human stomach cancers as revealed by pepsinogen immunohistochemistry and mucin histochemistry. Acta Pathol Jpn. 40:494–504. 1990.
16	Chang SK, Dohrman AF, Basbaum CB, et al: Localization of mucin (MUC2 and MUC3) messenger RNA and peptide expression in human normal intestine and colon cancer. Gastroenterology. 107:28–36. 1994.PubMed/NCBI
17	Morohara K, Tajima Y, Nakao K, et al: Gastric and intestinal phenotypic cell marker expressions in gastric differentiated-type carcinomas: association with E-cadherin expression and chromosomal changes. J Cancer Res Clin Oncol. 132:363–375. 2006. View Article : Google Scholar
18	Trejdosiewicz LK, Malizia G, Oakes J, et al: Expression of the common acute lymphoblastic leukaemia antigen (CALLA gp100) in the brush border of normal jejunum and jejunum of patients with coeliac disease. J Clin Pathol. 38:1002–1006. 1985. View Article : Google Scholar
19	Weiss AA, Babyatsky MW, Ogata S, et al: Expression of MUC2 and MUC3 mRNA in human normal, malignant, and inflammatory intestinal tissues. J Histochem Cytochem. 44:1161–1166. 1996. View Article : Google Scholar : PubMed/NCBI
20	Tsukita S, Furuse M and Itoh M: Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2:285–293. 2001. View Article : Google Scholar : PubMed/NCBI
21	Matsuda Y, Semba S, Ueda J, et al: Gastric and intestinal claudin expression at the invasive front of gastric carcinoma. Cancer Sci. 98:1014–1019. 2007. View Article : Google Scholar : PubMed/NCBI
22	Resnick MB, Gavilanez M, Newton E, et al: Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol. 36:886–892. 2005. View Article : Google Scholar
23	Cunningham SC, Kamangar F, Kim MP, et al: Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions. Cancer Epidemiol Biomarkers Prev. 15:281–287. 2006. View Article : Google Scholar
24	Fedwick JP, Lapointe TK, Meddings JB, et al: Helicobacter pylori activates myosin light-chain kinase to disrupt claudin-4 and claudin-5 and increase epithelial permeability. Infect Immun. 73:7844–7852. 2005. View Article : Google Scholar
25	Satake S, Semba S, Matsuda Y, et al: Cdx2 transcription factor regulates claudin-3 and claudin-4 expression during intestinal differentiation of gastric carcinoma. Pathol Int. 58:156–163. 2008. View Article : Google Scholar : PubMed/NCBI
26	Shinozaki A, Ushiku T, Morikawa T, et al: Epstein-Barr virus-associated gastric carcinoma: a distinct carcinoma of gastric phenotype by claudin expression profiling. J Histochem Cytochem. 57:775–785. 2009. View Article : Google Scholar
27	Sentani K, Oue N, Tashiro T, et al: Immunohistochemical staining of Reg IV and claudin-18 is useful in the diagnosis of gastrointestinal signet ring cell carcinoma. Am J Surg Pathol. 32:1182–1189. 2008. View Article : Google Scholar : PubMed/NCBI
28	Schlemper RJ, Riddell RH, Kato Y, et al: The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 47:251–255. 2000. View Article : Google Scholar : PubMed/NCBI
29	Hizawa K, Fuchigami T, Iida M, et al: Possible neoplastic transformation within gastric hyperplastic polyp. Application of endoscopic polypectomy. Surg Endosc. 9:714–718. 1995.
30	Kushima R and Hattori T: Histogenesis and characteristics of gastric-type adenocarcinomas in the stomach. J Cancer Res Clin Oncol. 120:103–111. 1993. View Article : Google Scholar : PubMed/NCBI
31	Park do Y, Srivastava A, Kim GH, et al: CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance. Mod Pathol. 23:54–61. 2010.PubMed/NCBI
32	Lauwers GY, Wahl SJ, Melamed J and Rojas-Corona RR: p53 expression in precancerous gastric lesions: an immunohistochemical study of PAb 1801 monoclonal antibody on adenomatous and hyperplastic gastric polyps. Am J Gastroenterol. 88:1916–1919. 1993.